Weight Loss Drugs in India: Ozempic and Wegovy Alternatives, Explained

India approved Ozempic and Wegovy in 2025 -- the same year surveys found nearly 40% of urban Indians clinically overweight or obese. At Rs 12,000 to Rs 18,000 a month, the drugs for weight loss that could help Indians, remain out of reach for most. But on March 21, 2026, semaglutide generics arrived at 60 to 70% lower cost.

Here is what doctors are actually prescribing in the meantime.

Why Are Ozempic and Wegovy Still Out of Reach in India?

Novo Nordisk launched Ozempic and Wegovy in 2025, but availability is only half the story. Both require cold-chain storage and specialist prescriptions, creating an access gap that price alone does not explain. For most patients outside metro cities, these weight loss drugs are effectively invisible.

Is Semaglutide Ever Prescribed for Weight Loss in India?

Yes, and widely. Ozempic was originally approved for diabetes, but doctors now prescribe it off-label for obesity. Sun Pharma and Dr. Reddy’s are queued to launch domestic generics the moment the patent expires, offering the most accessible ozempic alternative in India for weight loss yet.

What Is the Most Commonly Prescribed Weight Loss Drug in India?

Oral semaglutide (Rybelsus) leads in prescriptions for its needle-free convenience. But tirzepatide (Mounjaro) is fast becoming the preferred ozempic alternative in India for weight loss in metabolic clinics, with clinical trials showing users losing up to 22% of body weight, the results that have no precedent in obesity medicine.

Are There Any Approved GLP-1 Drugs for Obesity in India?

Zepbound, the obesity-specific formulation of tirzepatide, and Liraglutide (Saxenda) are both DCGI-approved alternatives, though Saxenda's daily injection requirement and modest outcomes make it a harder sell against newer drugs for weight loss.

Can Metformin Help with Weight Loss?

Metformin is the baseline treatment for PCOS-related weight gain and insulin resistance, and remains the most widely prescribed metabolic drug in India by volume. It is safer for long-term use but functions as a companion therapy, not a standalone solution.

What Is Next for Weight Loss Drugs in India?

Beyond Ozempic and Wegovy generics, oral tirzepatide formulations and next-generation GLP-1 drugs are in late-stage trials globally. India's biosimilar manufacturing strength means the country could become both a major consumer and exporter of affordable weight loss drugs within the decade.

(With inputs from yMedia)